# EDGAR Filing Document

**Accession Number:** 0001676047
**File Stem:** 0001213900-26-058507
**Filing Date:** 2026-5
**Character Count:** 39256
**Document Hash:** cc723af26f6a4d2570d3608dae309621
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-058507.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001213900-26-058507

**CONFORMED SUBMISSION TYPE**: 10-K/A

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20260131

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NutriBand Inc.
- **CENTRAL INDEX KEY:** 0001676047
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 811118176
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0131

**FILING VALUES:**
- **FORM TYPE:** 10-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40854
- **FILM NUMBER:** 26994293

**BUSINESS ADDRESS:**
- **STREET 1:** 121 S. ORANGE AVE.
- **STREET 2:** SUITE 1500
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32801
- **BUSINESS PHONE:** 407 377-6695

**MAIL ADDRESS:**
- **STREET 1:** 121 S. ORANGE AVE.
- **STREET 2:** SUITE 1500
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nutriband Inc.
- **DATE OF NAME CHANGE:** 20160601

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**AMENDMENT NO. 1**

**TO**

**FORM 10-K**

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended January 31, 2026

or

☐ **TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from __________ to __________

Commission file number 000-40854

**NUTRIBAND INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **81-1118176** |
| (State or other jurisdiction of<br> Incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **121 South Orange Ave., Suite 1500, Orlando, FL** | **32801** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: (407) 377-6695

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | NTRB | The Nasdaq Stock Market LLC |
| Warrants | NTRBW | The Nasdaq Stock Market LLC |

---

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ☐

Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

\* \* \*

**EXPLANATORY NOTE**

**NUTRIBAND EXECUTIVE CLAWBACK POLICY**

The Company is filing this Amendment No. 1 to its Form 10-K for the fiscal year ended January 31, 2026 (the "2026 10-K") to file the Policy Relating to Recovery of Erroneously Awarded Compensation (the 'Clawback Policy') as Exhibit 97.1 to the 2026 10-K, which was omitted from the original filing. The Company adopted the Clawback Policy on January 24, 2026, in compliance with applicable NASDAQ listing standards and SEC Rule 10D-1, but failed to include the policy as an exhibit in the original filing of the 2026 10-K. This Amendment to Item 15 of the Company's 2026 10-K does not reflect events occurring after the filing of the original 2026 **10-K** or modify or **update** the disclosure contained therein in an**y** way other than to reflect the adoption of the Clawback Policy.

**PART IV**

**ITEM 15 Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | <br>**Description** |
| 1.1 | [Reserved] |
| 3.1A | [Articles of Incorporation.<sup>(1)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex3ia_nutriband.htm) |
| 3.1B | [Amendment to Articles of Incorporation, filed May 12, 2016.<sup>(1)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex3ib_nutriband.htm) |
| 3.1 | [Certificate of Amendment filed January 21, 2020. (Filed as Exhibit 3.1 to the Company's Current Report](http://www.sec.gov/Archives/edgar/data/1676047/000121390020001906/f8k012120ex3-1_nutribandinc.htm) [on Form 8-K, filed January 27, 2020).](http://www.sec.gov/Archives/edgar/data/1676047/000121390020001906/f8k012120ex3-1_nutribandinc.htm) |
| 3.1C | [Certificate of Change, filed with the Nevada Secretary of State on August 4, 2022.<sup>(13)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390022046093/ea164097ex3-1c_nutriband.htm) |
| 3.1D | [Amendment to Articles of Incorporation, filed with the Nevada Secretary of State on July 16, 2025.<sup>(21)</sup>](https://www.sec.gov/Archives/edgar/data/1676047/000121390025064355/ea024911601ex3-1d_nutri.htm) |
| 3.2 | [By-laws<sup>(1)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex3ii_nutriband.htm) |
| 3.2B | [Amended and Restated By-Laws adopted January 21, 2022.<sup>(12)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390022004031/ea154565ex3-2a_nutriband.htm) |
| 4.3 | [Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC](http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-1_nutriband.htm) [and Platinum Point Capital LLC<sup>(6)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-1_nutriband.htm) |
| 4.4 | [Form of convertible 6% promissory note issued pursuant to Exhibit 4.3 <sup>(6)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-2_nutriband.htm) |
| 4.10 | [Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street](http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-3_nutriband.htm) [Capital LLC<sup>(6)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390019021870/f8k103019ex4-3_nutriband.htm) |
| 4.14† | [2021 Employee Stock Option Plan.<sup>(11)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021057079/ea149845ex10-1_nutribandinc.htm) |
| 4.15† | [Form of Stock Option Grant Notice.<sup>(11)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021057079/ea149845ex10-2_nutribandinc.htm) |
| 4.16 | [Form of Common Stock Purchase Warrant issued in the Company's initial public offering in 2021<sup>(9)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021050881/ea148206ex4-12_nutriband.htm) |
| 4.17 | [Form of Warrant issued to the Representative.<sup>(14)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390023051508/ea180127ex4-17_nutribandinc.htm) |
| 4.18† | [2024 Amended and Restated Stock Option Plan, adopted March 20, 2024.<sup>(15)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390024027338/ea020284801ex4-16_nutri.htm) |
| 4.19 | [Form of Common Stock Purchase Warrant issued in 2024 Equity Financi1ng <sup>(18)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390024035276/ea020449001ex4-19_nutriband.htm) |
| 5.1 | [Reserved] |
| 10.1 | [Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an](http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex10i_nutriband.htm) [Ireland corporation, and Gareth Sheridan and/or his nominee<sup>(1)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390016013961/f1012g2016ex10i_nutriband.htm) |
| 10.4 | [Acquisition agreement dated April 5, 2018 between the Company and 4P Therapeutics LLC.<sup>(3)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390018004227/f8k041018ex99-2_nutriband.htm) |
| 10.5† | [Form of agreement with independent directors.<sup>(4)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390019006792/f10k2019ex10-4_nutribandinc.htm) |
| 10.6 | [Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea](http://www.sec.gov/Archives/edgar/data/1676047/000121390019006792/f10k2019ex10-5_nutribandinc.htm) [(Best Choice), Inc.<sup>(4)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390019006792/f10k2019ex10-5_nutribandinc.htm) |
| 10.15† | [Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company.<sup>(5)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-15_nutriband.htm) |
| 10.16† | [Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company.<sup>(5)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-16_nutriband.htm) |
| 10.17† | [Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company.<sup>(5)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-17_nutriband.htm) |
| 10.18† | [Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company.<sup>(5)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390020012861/ea122002ex10-18_nutriband.htm) |
| 10.19 | [Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products,](http://www.sec.gov/Archives/edgar/data/1676047/000121390020025377/ea126478ex10-19_nutribandinc.htm) [LLC.<sup>(7)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390020025377/ea126478ex10-19_nutribandinc.htm) |

---

---

| | |
|:---|:---|
| 10.20 | [Security Agreement, between the Company and Pocono Coated Products, LLC.<sup>(7)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390020025377/ea126478ex10-20_nutribandinc.htm) |
| 10.21 | [Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC.<sup>(7)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390020025377/ea126478ex10-21_nutribandinc.htm) |
| 10.22 | [License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd.<sup>(8)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021014753/ea137408ex10-22_nutriband.htm) |
| 10.23 | [Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd.<sup>(8)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021014753/ea137408ex10-23_nutriband.htm) |
| 10.24 | [Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd.<sup>(8)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021014753/ea137408ex10-24_nutriband.htm) |
| 10.25 | [Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and](http://www.sec.gov/Archives/edgar/data/1676047/000121390021046170/ea146824ex10-25_nutriband.htm) [Pocono Coated Products, LLC<sup>(8a)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021046170/ea146824ex10-25_nutriband.htm) |
| 10.26 | [Services Agreement dated October 4, 2021, between Active Intelligence, LLC and Diomics](http://www.sec.gov/Archives/edgar/data/1676047/000121390021052451/ea148731ex10-26_nutriband.htm) [Corporation.<sup>(10)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390021052451/ea148731ex10-26_nutriband.htm) |
| 10.27† | [Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan.<sup>(12)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390022004031/ea154565ex10-27_nutriband.htm) |
| 10.28† | [Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik.<sup>(12)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390022004031/ea154565ex10-28_nutriband.htm) |
| 10.29† | [Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman.<sup>(12)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390022004031/ea154565ex10-29_nutriband.htm) |
| 10.30 | [Creditline Promissory Note, dated July 13, 2023. <sup>(16)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390023056939/ea181821ex10-30_nutriband.htm) |
| 10.31 | [Conversion Agreement, dated December 19, 2023.<sup>(17)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390023100093/ea190927ex10-31_nutriband.htm) |
| 10.32 | [Form of Subscription Agreement for April 19, 2024 Equity Financing <sup>(19)</sup>](https://www.sec.gov/Archives/edgar/data/1676047/000121390024035276/ea020449001ex10-32_nutriband.htm) |
| 10.33 | [Form of Note Conversion Agreement dated May 13, 2024<sup>20</sup>](https://www.sec.gov/Archives/edgar/data/1676047/000121390024045330/ea020654401ex10-33_nutri.htm) |
| 10.35 | [Commercial Development and Clinical Supply Agreement ("Agreement"), made on January 4, 2023, between Kindeva Drug Delivery, L.P. and 4P Therapeutics, LLC., filed as Exhibit 10.35 to the Company's Annual Report on Form 10-K, filed with the SEC on April 28, 2025.](http://www.sec.gov/Archives/edgar/data/1676047/000121390025036201/ea023904801ex10-35_nutriband.htm) |
| 10.36 | [Amendment No. 1, dated as of February 4, 2025, to the Commercial Development and Clinical Supply Agreement, by and between Kindeva Drug Delivery L.P. and 4P Therapeutics, LLC., filed as Exhibit 10.36 to the Company's Annual Report on Form 10-K, filed with the SEC on April 28, 2025.](http://www.sec.gov/Archives/edgar/data/1676047/000121390025036201/ea023904801ex10-36_nutriband.htm) |
| 21.1 | [List of Subsidiaries of Nutriband Inc.<sup>(14)</sup>](http://www.sec.gov/Archives/edgar/data/1676047/000121390023051508/ea180127ex21-1_nutribandinc.htm) |
| 23.1 | [Reserved] |
| 31.1 | [Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.\*](ea029087401ex31-1.htm) |
| 31.2 | [Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.\*](ea029087401ex31-2.htm) |
| 32.1 | [Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley.\*](ea029087401ex32-1.htm) |
| 32.2 | [Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley.\*](ea029087401ex32-2.htm) |
| 97.1 | [Executive Compensation Clawback Policy†\*](ea029087401ex97-1.htm) |
| 101.INS | Inline XBRL Instance Document.\* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.\* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document.\* |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document.\* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| 107 | Filing Fee Table |

---

---

| | |
|:---|:---|
| \* | Filed herewith. |
| † | Executive compensation plan or arrangement. |
| (1) | Filed as exhibit to the Company's registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference. |

---

&nbsp;&nbsp;&nbsp;&nbsp;(2) Filed as an exhibit to the Company's report on Form 8-K, which was filed with the Commission on January 27, 2020 and incorporated herein by reference.

(3) Filed as an exhibit to the Company's report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference.

(4) Filed as an exhibit to the Company's annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Filed as an exhibit to the Company's Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Filed as an exhibit to the Company's report on Form 8-K, which was filed with the Commission on November 4, 2019, and incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Filed as an exhibit to the Company's report on Form 8-K, which was filed with the Commission on September 4, 2020, and incorporated herein by reference.

(8) Filed as exhibits to the Company's report on Form 8-K, which was filed with the Commission on March 11, 2021, and incorporated herein by reference.

(8a) Filed as an exhibit to the Company's report on Form 8-K, which was filed with the Commission on September 1, 2021, and incorporated herein by reference.

(9) Filed as Exhibit 4.12 to Amendment 2 to the Company's Registration Statement on Form S-1, which was filed with the Commission on October 1, 2021.

(10) Filed as an exhibit to the Company's Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on October 12, 2021, and incorporated herein by reference.

(11) Filed as an exhibit to the Company's Registration Statement on Form S-8, which was filed with the Commission on November 5, 2021, and incorporated herein by reference.

(12) Filed as an exhibit to the Company's Current Report on Form 8-K, which was filed with the Commission on January 27, 2022, and incorporated herein by reference.

(13) Filed as Exhibit 3.1C to the Company's Current Report on Form 8-K, which was filed with the Commission on August 10, 2022, and incorporated herein by reference.

(14) Filed as an exhibit to the Company's Registration Statement on Form S-1, which was filed with the Commission on June 26, 2023, and incorporated herein by reference

(15) Filed as Exhibit 4.16 to the Company's Amendment No. to its Current Report on Form 8-K, which was filed with the Commission on March 28, 2024 and incorporated herein by reference.

(16) Filed as Exhibit 10.30 to the Company's Current Report on Form 8-K, which was filed with the Commission on July 14, 2023.

(17) Filed as Exhibit No. 10.31 to the Company's Current Report on Form 8-K, which was filed with the Commission on December 29, 2023.

(18) Filed as Exhibit No. 4.19 to the Company's Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.

(19) Filed as Exhibit No. 10.32 to the Company's Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.

(20) Filed as Exhibit No. 10.33 to the Company's Current Report on Form 8-K, which was filed with the Commission on May 21, 2024.

(21) Filed as Exhibit 3.1D to the Company's Current Report on form 8-K, filed with the Commission on July 14, 2025.

*(b) Financial Statement Schedules*

All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 18, 2026

---

| | |
|:---|:---|
| **NUTRIBAND INC.** | **NUTRIBAND INC.** |
| By: | /s/ Gareth Sheridan |
|  | Gareth Sheridan |
|  | Chief Executive Officer |
| By: | /s/ Gerald Goodman |
|  | Gerald Goodman |
|  | Chief Financial Officer<br> (Principal Financial and Accounting Officer) |

---

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Gareth Sheridan | Chief Executive Officer and Director | May 18, 2026 |
| Gareth Sheridan |  |  |
| /s/ Serguei Melnik | Director | May 18, 2026 |
| Serguei Melnik |  |  |
|  | Director |  |
| Sergei Glinka |  |  |
| /s/ Radu Bujoreanu | Director | May 18, 2026 |
| Radu Bujoreanu |  |  |
| /s/ Mark Hamilton | Director | May 18, 2026 |
| Mark Hamilton |  |  |
| /s/ Stefani Mancas | Director | May 18, 2026 |
| Stefani Mancas |  |  |
| /s/ Irina Gram | Director | May 18, 2026 |
| Irina Gram |  |  |
|  | Director |  |
| Viorica Carlig |  |  |
|  | Director |  |
| Alessandro Pudu |  |  |

---

## Exhibit 31.1

**Exhibit 31.1**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

CERTIFICATION

I, Gareth Sheridan, certify that:

1. I have reviewed this Amendment to the Annual Report on Form
10-K of Nutriband Inc.;

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal
control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons
performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting;

---

| | |
|:---|:---|
| DATE: May 18, 2026 | /s/ Gareth Sheridan |
|  | Gareth Sheridan, <br> Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

CERTIFICATION

I, Gerald Goodman, certify that:

1. I have reviewed this Amendment to the Annual Report on Form 10-K
of Nutriband Inc.;

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal
control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons
performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting;

---

| | |
|:---|:---|
| DATE: May 18, 2026 | /s/ Gerald Goodman |
|  | Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Amendment to the Annual Report of Nutriband Inc. (the "Company") on Form 10-K for the year ended January 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gareth Sheridan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| |
|:---|
| /s/ Gareth Sheridan |
| Gareth Sheridan, <br> Chief Executive Officer |
| May 18, 2026 |

---

The foregoing certification is not filed with the Securities and Exchange Commission as part of the Form 10-K or as a separate disclosure document and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespectively of any general incorporation language contained in such filing.

## Exhibit 32.2

**Exhibit 32.2**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Amendment to the Annual Report of Nutriband Inc. (the "Company") on Form 10-K for the year ended January 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gerald Goodman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| |
|:---|
| /s/ Gerald Goodman |
| Gerald Goodman, <br> Chief Financial Officer |
| May 18, 2026 |

---

The foregoing certification is not filed with the Securities and Exchange Commission as part of the Form 10-K or as a separate disclosure document and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespectively of any general incorporation language contained in such filing.

## Exhibit 97.1

**Exhibit 97.1**

**<br> NUTRIBAND, INC.<br> CLAWBACK POLICY<br> (Effective October 3, 2023)**

**Purpose**

The Board of Directors (the "***Board***") of Nutriband Inc., a Nevada corporation (together with its subsidiaries, the "***Company***"), has adopted this policy to ensure that executive officers do not retain the benefits of certain erroneously awarded compensation and also to further incent conduct intended to improve the overall quality and reliability of financial reporting.

**Definitions**

For purposes of this policy, the following definitions shall apply:

● "  ***Accounting Restatement***" means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

● "  ***Erroneously Awarded Compensation***" means the amount of Incentive-Based Compensation Received by an Executive Officer that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had it been determined based on the restated amounts, which amount must be computed without regard to any taxes paid by such Executive Officer.

● "  ***Executive Officer***" means the Company's chief executive officer, chief operating officer, chief financial officer, president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the issuer in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the issuer. Executive officers of the Company's subsidiaries are deemed executive officers of the Company if they perform such policy making functions. Executive Officers for purposes of this policy includes, at a minimum, such executive officers identified as such in the Company's Annual Report on Form 10-K.

● "  ***Financial Reporting Measure***" are measures that are determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the U.S. Securities and Exchange Commission.

● "  ***Incentive-Based Compensation***" means any compensation that is granted, earned or vested based wholly or in part upon the attainment of any Financial Reporting Measure.

● "  ***Received***" with respect to Incentive-Based Compensation means the fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.

● "  ***Recovery Period***" means the three (3) completed fiscal years immediately preceding the date that the Company is required to prepare an Accounting Restatement, which date is the earlier to occur of (a) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement. In addition to these last three (3) completed fiscal years, the Recovery Period also applies to any transition period (that results from a change in the Company's fiscal year) within or immediately following those three (3) completed fiscal years. However, a transition period between the last day of the Company's previous fiscal year end and the first day of its new fiscal year that comprises a period of nine (9) to twelve (12) months would be deemed a completed fiscal year.

**Policy Statement**

In the event the Company is required to prepare an Accounting Restatement, then the Company will recover reasonably promptly the amount of Erroneously Awarded Compensation that is Received by any current or former Executive Officer during the Recovery Period.

Additionally, the Board, in its sole discretion and subject to applicable law, may seek to recover Incentive-Based Compensation or discretionary compensation received by any current or former Executive Officer during the Recovery Period in the event that such Executive Officer's willful engagement in conduct which is demonstrably or materially injurious to the Company, monetarily or otherwise.

**Exceptions**

The Company will not be required to enforce this policy to the extent that the Compensation Committee (the "***Committee***") of the Board determines that (i) recovery would be impracticable and (ii) one of the conditions of (A) or (B) are satisfied:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) The direct expense paid to a third party to assist in enforcing this policy would exceed the amount to be recovered; <u>provided</u>, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company has made a reasonable attempt to recover such amounts, documented such reasonable attempt(s) to recover, and provided that documentation to the Nasdaq Capital Market (the "  ***NASDAQ*** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to the Company's employees, to fail to meet the requirements of the Internal Revenue Code of 1986, as amended.

**Prohibition on Indemnity or Reimbursement**

The Company is prohibited from indemnifying any current or former Executive Officer against the loss of any Erroneously Awarded Compensation or paying or reimbursing such Executive Officers for insurance premiums to recover losses incurred under this policy.

**Administration of Policy**

This policy is intended to comply with Nasdaq Rule 5608 and SEC 10D-1(collectively, the "***Applicable Rules***"). The Committee have authority to interpret and administer this policy in a manner consistent with the Applicable Rules and to make all determinations with respect to this policy in its sole discretion which shall be final and binding on all parties; <u>provided</u>, <u>however</u>, that, as further described above, the Board shall retain discretion to determine whether amounts shall be recovered in the absence of an Accounting Restatement.